{"groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the pharmacokinetic (PK)-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to hematopoietic stem cell transplant (HSCT).","id":"FG000","title":"IV Busulfan"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Subject Met Withdrawal Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Subject was Withdrawn by Investigator"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Subject Withdrew Consent to Participate"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}